Hologic, Inc. (NASDAQ:HOLX) Receives $87.00 Average PT from Brokerages

Shares of Hologic, Inc. (NASDAQ:HOLX) have been assigned an average recommendation of “Hold” from the nine research firms that are covering the company, MarketBeat reports. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $87.00.

Several brokerages have commented on HOLX. Raymond James lifted their price objective on shares of Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Wednesday, April 10th. StockNews.com downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and increased their price target for the stock from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Finally, Evercore ISI boosted their price objective on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th.

Hologic Price Performance

Shares of HOLX opened at $75.10 on Tuesday. Hologic has a 12-month low of $64.02 and a 12-month high of $87.88. The stock has a market cap of $17.63 billion, a P/E ratio of 35.59, a P/E/G ratio of 2.54 and a beta of 1.00. The business’s fifty day moving average is $75.71 and its 200 day moving average is $72.50. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The company’s revenue for the quarter was down 5.7% on a year-over-year basis. During the same quarter last year, the company earned $1.07 earnings per share. Sell-side analysts anticipate that Hologic will post 4.02 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now owns 1,572 shares in the company, valued at $119,802.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the transaction, the director now owns 48,611 shares in the company, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. Insiders sold 32,846 shares of company stock worth $2,473,443 in the last quarter. 1.75% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Massmutual Trust Co. FSB ADV increased its position in shares of Hologic by 24.7% during the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after buying an additional 137 shares during the period. Belpointe Asset Management LLC raised its position in shares of Hologic by 18.0% in the 1st quarter. Belpointe Asset Management LLC now owns 937 shares of the medical equipment provider’s stock worth $76,000 after acquiring an additional 143 shares in the last quarter. Deseret Mutual Benefit Administrators lifted its stake in shares of Hologic by 42.2% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 155 shares during the period. Arizona State Retirement System boosted its position in shares of Hologic by 0.3% during the fourth quarter. Arizona State Retirement System now owns 67,319 shares of the medical equipment provider’s stock valued at $4,810,000 after purchasing an additional 172 shares in the last quarter. Finally, Cooper Financial Group grew its stake in Hologic by 1.9% in the third quarter. Cooper Financial Group now owns 9,502 shares of the medical equipment provider’s stock worth $659,000 after purchasing an additional 174 shares during the period. Institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.